☆ 4.7 Meeting Abstract

A Phase I Study Evaluating the Safety and Persistence of Allorestricted WT1-TCR Gene Modified Autologous T Cells in Patients with High-Risk Myeloid Malignancies Unsuitable for Allogeneic Stem Cell Transplantation

BLOOD (2019)

Journal

BLOOD

Volume 134, Issue -, Pages -

Publisher

AMER SOC HEMATOLOGY

DOI: 10.1182/blood-2019-128044

Keywords

-

Categories

Hematology

Funding

MRC [MR/P019072/1] Funding Source: UKRI

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Immunology

Features of the TCR repertoire associate with patients' clinical and molecular characteristics in acute myeloid leukemia

Mateusz Pospiech, Mukund Tamizharasan, Yu-Chun Wei, Advaith Maya Sanjeev Kumar, Mimi Lou, Joshua Milstein, Houda Alachkar

Summary: This study examined the association between TCR repertoire features in adult AML patients and their clinical and molecular characteristics using two computational tools. The study found that unique TCR clones were correlated with patients' white blood cell counts and blast percentages, and also correlated with T cells inhibitory signal genes. These findings suggest the presence of exhausted T cell phenotypes in AML.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Hematology

Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies

Caner Saygin, Gregory Roloff, Christopher N. Hahn, Rakchha Chhetri, Saar Gill, Hany Elmariah, Chetasi Talati, Emma Nunley, Guimin Gao, Aelin Kim, Michael Bishop, Satyajit Kosuri, Soma Das, Deepak Singhal, Parvathy Venugopal, Claire C. Homan, Anna Brown, Hamish S. Scott, Devendra Hiwase, Lucy A. Godley

Summary: There is growing recognition that pathogenic germ line variants play a role in the development of hematopoietic cancers. Patients with myeloid malignancies and deleterious germ line DDX41 variants have a higher incidence of severe acute GVHD. The use of posttransplant cyclophosphamide can reduce the risk of severe acute GVHD in these patients.

BLOOD ADVANCES (2023)

Add to Collection

Article Hematology

Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies

Amir T. Fathi, Haesook T. Kim, Robert J. Soiffer, Mark J. Levis, Shuli Li, Annette S. Kim, Alice S. Mims, Zachariah DeFilipp, Areej El-Jawahri, Steven L. McAfee, Andrew M. Brunner, Rupa Narayan, Laura W. Knight, Devon Kelley, Aj S. Bottoms, Lindsey H. Perry, Jonathan L. Wahl, Jennifer Brock, Elayne Breton, Vincent T. Ho, Yi-Bin Chen

Summary: This study evaluated the efficacy of enasidenib maintenance therapy in patients with IDH2-mutated myeloid malignancies following hematopoietic cell transplantation. The results demonstrated that enasidenib is safe and well-tolerated and has potential as a maintenance therapy for patients with IDH2-mutated AML. Further research is warranted.

BLOOD ADVANCES (2022)

Add to Collection

Review Oncology

The importance of evaluating specific myeloid malignancies in epidemiological studies of environmental carcinogens

K. A. Mundt, L. D. Dell, P. Boffetta, E. M. Beckett, H. N. Lynch, V. J. Desai, C. K. Lin, W. J. Thompson

Summary: Epidemiological studies on specific myeloid malignancies are limited and inconsistent, with different chemical agents showing varied associations with different types of myeloid malignancies. Further research focusing on specific myeloid malignancies is needed for clearer understanding of their etiological relationships with chemical agents.

BMC CANCER (2021)

Add to Collection

Editorial Material Oncology

Will allogeneic CAR T cells for CD19+ malignancies take autologous CAR T cells 'off the shelf'?

Amanda M. DiNofia, Stephan A. Grupp

Summary: This study reports the use of allogeneic anti-CD19 CAR T cells in 21 pediatric and adult patients with acute lymphoblastic leukemia. The results provide some insights into the potential of allogeneic CAR T cell therapy as a replacement for autologous CAR T cell therapy, although more data are needed for further comparisons.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Add to Collection

Article Hematology

αβ T-cell graft depletion for allogeneic HSCT in adults with hematological malignancies

Moniek A. de Witte, Anke Janssen, Klaartje Nijssen, Froso Karaiskaki, Luuk Swanenberg, Anna van Rhenen, Rick Admiraal, Lotte van der Wagen, Monique C. Minnema, Eefke Petersen, Reinier A. P. Raymakers, Kasper Westinga, Trudy Straetemans, Constantijn J. M. Halkes, Jaap-Jan Boelens, Jurgen Kuball

Summary: A multicenter study evaluated the outcome of alpha beta T-cell depleted allogeneic hematopoietic stem cell transplantation in adults, with only 26% developing aGVHD grades 2-4 within 100 days and a low incidence of cGVHD after 2 years. Prophylactic donor lymphocyte infusion improved the condition of some patients.

BLOOD ADVANCES (2021)

Add to Collection

Article Immunology

Different recovery patterns of CMV-specific and WT1-specific T cells in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: Impact of CMV infection and leukemia relapse

Xiao-Hua Luo, Thomas Poiret, Zhenjiang Liu, Qingda Meng, Anurupa Nagchowdhury, Per Ljungman

Summary: In allogeneic hematopoietic cell transplantation, reconstitution of virus-specific T cells and leukemia-specific T cells is crucial for patient protection. Cytomegalovirus (CMV) infection is a significant cause of morbidity and mortality after transplantation. Recent data suggests that CMV reactivation is associated with a reduced risk of leukemia relapse in AML patients. Our study found that CMV-specific CD8+ T cells reconstituted faster than WT1-specific CD8+ T cells. Furthermore, CMV-specific T cells exhibited lower exhaustion markers and higher functionality compared to WT1-specific T cells. Notably, patients with CMV reactivation had a higher frequency of CMV-specific T cells and different expression patterns of Eomes and T-bet compared to patients without CMV reactivation. The kinetics of CMV-specific and WT1-specific T cell reconstitution may be associated with measurable residual disease and leukemia relapse. These findings suggest that CMV reactivation may influence WT1-specific T cell reconstitution after allo-HSCT, potentially affecting the remission/relapse of AML.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Oncology

Bone marrow CD34+molecular chimerism as an early predictor of relapse after allogeneic stem cell transplantation in patients with acute myeloid leukemia

Michele Malagola, Nicola Polverelli, Alessandra Beghin, Federica Bolda, Marta Comini, Mirko Farina, Enrico Morello, Vera Radici, Eugenia Accorsi Buttini, Simona Bernardi, Federica Re, Alessandro Leoni, Davide Bonometti, Duilio Brugnoni, Arnalda Lanfranchi, Domenico Russo

Summary: We retrospectively analyzed the impact of bone marrow CD34+ molecular chimerism and WT1 on the outcome of AML patients submitted to allogeneic stem cell transplantation. The cumulative incidence of relapse was significantly lower in patients with high donor chimerism on CD34+ cells and low WT1 levels at 1st and 3rd month post-transplantation. By combining chimerism and WT1 at 3rd month, patients with intermediate prognosis could be identified.

FRONTIERS IN ONCOLOGY (2023)

Add to Collection

Article Oncology

Day+60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients

Patrizia Chiusolo, Elisabetta Metafuni, Gessica Minnella, Sabrina Giammarco, Silvia Bellesi, Monica Rossi, Federica Sora, Maria Assunta Limongiello, Filippo Frioni, Nicola Piccirillo, Maria Bianchi, Caterina Giovanna Valentini, Luciana Teofili, Simona Sica, Andrea Bacigalupo

Summary: The aim of this study was to evaluate the role of WT1 expression after allogeneic stem cell transplantation (alloHSCT) in patients with acute myeloid leukemia (AML). The results showed that WT1 expression at day 60 is a significant predictor of relapse, particularly when tested on CD34+ selected bone marrow cells.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Hematology

Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation

Kevin-James Wattebled, Elodie Drumez, Valerie Coiteux, Leonardo Magro, Micha Srour, Paul Chauvet, Bruno Quesnel, Alain Duhamel, Ibrahim Yakoub-Agha, David Beauvais

Summary: Single-agent AZA does not appear to be an optimal drug for preventing posttransplant relapse in patients with high-risk myeloid malignancies. This study highlights the need for prospective studies of alternative therapies or combination approaches in the post-transplant setting.

ANNALS OF HEMATOLOGY (2022)

Add to Collection

Article Oncology

Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Talha Badar, Ehab Atallah, Rory Shallis, Antoine N. Saliba, Anand Patel, Jan P. Bewersdorf, Justin Grenet, Maximilian Stahl, Adam Duvall, Madelyn Burkart, Neil Palmisiano, Danielle Bradshaw, Michal Kubiak, Shira Dinner, Aaron D. Goldberg, Yasmin Abaza, Guru Subramanian Guru Murthy, Vamsi Kota, Mark R. Litzow

Summary: We conducted a multi-center study to analyze factors predicting survival among TP53-mutated (m) AML patients receiving allogeneic hematopoietic stem cell transplant (allo-HSCT) in the recent era. The results showed that complete remission at day 100 post allo-HSCT and occurrence of chronic GVHD are significant predictors for better event-free survival (EFS) and overall survival (OS). Our findings suggest that allo-HSCT offers the best opportunity for long-term improvement in TP53m AML patients.

LEUKEMIA (2023)

Add to Collection

Article Cell Biology

Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study

Yongxian Hu, Yali Zhou, Mingming Zhang, Houli Zhao, Guoqing Wei, Wengang Ge, Qu Cui, Qitian Mu, Gong Chen, Lu Han, Tingting Guo, Jiazhen Cui, Xiaoyan Jiang, Xiujun Zheng, Shuhui Yu, Xiaolong Li, Xingwang Zhang, Mingxi Chen, Xiuju Li, Ming Gao, Kang Wang, Cheng Zu, Hao Zhang, Xiaohong He, Yanbin Wang, Dongrui Wang, Jiangtao Ren, He Huang

Summary: This study developed healthy donor-derived CD7-targeting allogeneic CAR-T cells with genetic modifications and conducted a phase I clinical trial. The results demonstrated the encouraging safety and efficacy profiles of the RD13-01 allogeneic CAR-T cells for CD7(+) tumors.

CELL RESEARCH (2022)

Add to Collection

Article Pharmacology & Pharmacy

Safety and efficacy of a modified busulfan/cyclophosphamide conditioning regimen incorporating cladribine for autologous hematopoietic stem cell transplantation in acute myeloid leukemia

Yuan-Yuan Shi, Zeng-Yan Liu, Gui-Xin Zhang, Yi He, Ming-Zhe Han, Si-Zhou Feng, Rong-Li Zhang, Er-Lie Jiang

Summary: This study explores the safety and effectiveness of a cladribine-based conditioning regimen for autologous hematopoietic stem cell transplantation in patients with acute myeloid leukemia. The results indicate that this regimen is a successful and safe approach for AML treatment.

FRONTIERS IN PHARMACOLOGY (2023)

Add to Collection

Article Hematology

Conditioning therapy with N-acetyl-L-cysteine, decitabine and modified BUCY regimen for myeloid malignancies patients prior to allogeneic hematopoietic stem cell transplantation

Yaqiong Tang, Ziyan Zhang, Silu Liu, Yifang Yao, Tingting Pan, Jiaqian Qi, Huizhu Kang, Yuejun Liu, Chengsen Cai, Meng Zhou, Xuefeng He, Xiaohui Hu, Xiao Ma, Depei Wu, Yue Han

Summary: Conditioning therapy is crucial for recipients of hematopoietic stem cell transplant (HSCT) and the addition of decitabine and NAC to mBUCY regimen shows promising outcomes for myeloid malignancies patients. Platelet recovery and relapse rates were improved in the group receiving decitabine, NAC, and mBUCY therapy compared to the group only receiving mBUCY regimen. The addition of decitabine and NAC also resulted in lower levels of intracellular reactive oxygen species (ROS) and higher overall survival rates after 3 years.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Article Hematology

Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis

Krischan Braitsch, Alix Schwarz, Katrin Koch, Mara Hubbuch, Helge Menzel, Ulrich Keller, Katharina S. Goetze, Florian Bassermann, Peter Herhaus, Mareike Verbeek

Summary: This retrospective analysis compares the efficacy and tolerability of reduced intensity conditioning regimens, Flu/Treo and FLAMSA-RIC, in patients with myeloid malignancies undergoing alloSCT. The results indicate that there is no significant difference in engraftment, survival, relapse, transplant-related mortality, and graft-versus-host disease between the two regimens.

ANNALS OF HEMATOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome

A. Magnani, M. Semeraro, F. Adam, C. Booth, L. Dupre, E. C. Morris, A. Gabrion, C. Roudaut, D. Borgel, A. Toubert, E. Clave, C. Abdo, G. Gorochov, R. Petermann, M. Guiot, M. Miyara, D. Moshous, E. Magrin, A. Denis, F. Suarez, C. Lagresle, A. M. Roche, J. Everett, A. Trinquand, M. Guisset, J. Xu Bayford, S. Hacein-Bey-Abina, A. Kauskot, R. Elfeky, C. Rivat, S. Abbas, H. B. Gaspar, E. Macintyre, C. Picard, F. D. Bushman, A. Galy, A. Fischer, E. Six, A. J. Thrasher, M. Cavazzana

Summary: This article presents the long-term follow-up results of gene therapy for patients with Wiskott-Aldrich syndrome, showing that lentiviral gene therapy provides sustained clinical benefits for these patients.

NATURE MEDICINE (2022)

Add to Collection

Article Hematology

Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity: an EBMT IEWP study

Michael H. Albert, Tiarlan Sirait, Dirk-Jan Eikema, Katerina Bakunina, Claudia Wehr, Felipe Suarez, Maria Laura Fox, Nizar Mahlaoui, Andrew R. Gennery, Arjan C. Lankester, Rita Beier, Maria Ester Bernardo, Venetia Bigley, Caroline A. Lindemans, Siobhan O. Burns, Ben Carpenter, Jaroslaw Dybko, Tayfun Gungor, Fabian Hauck, Su Han Lum, Dmitry Balashov, Roland Meisel, Despina Moshous, Ansgar Schulz, Carsten Speckmann, Mary A. Slatter, Brigitte Strahm, Duygu Uckan-Cetinkaya, Isabelle Meyts, Tanja C. Vallee, Robert Wynn, Benedicte Neven, Emma C. Morris

Summary: Allogeneic hematopoietic stem cell transplantation (HSCT) is the gold standard curative therapy for infants and children with inborn errors of immunity (IEI), but its adoption for adolescents and adults with IEI has been delayed due to lack of outcome data and perceived high risk of transplant-related mortality. This large retrospective, multicenter study reports on 329 IEI patients who underwent HSCT between 2000 and 2019. The study found that the overall survival (OS) and event-free survival (EFS) rates were 78% and 65% at 1 year post-HSCT, and 71% and 62% at 5 years post-HSCT, respectively. The study also identified risk factors for adverse outcomes, providing important evidence for patient selection.

BLOOD (2022)

Add to Collection

Article Oncology

Genome-Edited T Cell Therapies

Giorgio Ottaviano, Waseem Qasim

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2022)

Add to Collection

Correction Biochemistry & Molecular Biology

Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome (Aug, 10.1038/s41591-021-01641-x, 2022)

A. Magnani, M. Semeraro, F. Adam, C. Booth, L. Dupre, E. C. Morris, A. Gabrion, C. Roudaut, D. Borgel, A. Toubert, E. Clave, C. Abdo, G. Gorochov, R. Petermann, M. Guiot, M. Miyara, D. Moshous, E. Magrin, A. Denis, F. Suarez, C. Lagresle, A. M. Roche, J. Everett, A. Trinquand, M. Guisset, J. Xu Bayford, S. Hacein-Bey-Abina, A. Kauskot, R. Elfeky, C. Rivat, S. Abbas, H. B. Gaspar, E. Macintyre, C. Picard, F. D. Bushman, A. Galy, A. Fischer, E. Six, A. J. Thrasher, M. Cavazzana

NATURE MEDICINE (2022)

Add to Collection

Review Hematology

Genome-edited allogeneic donor universal chimeric antigen receptor T cells

Waseem Qasim

Summary: Genome editing technologies, such as CRISPR/Cas9, are being used to overcome the challenges of allogeneic T-cell therapy for blood malignancies by disrupting TCR alpha beta and preventing graft-versus-host disease. Premanufactured banks of allogeneic donor-derived CAR T cells could help address the complex logistics and high costs of autologous therapies, if HLA-mismatched T-cell therapy can be successfully addressed. Clinical trials will be crucial in determining the safety and efficacy of these modified T-cell therapies.

BLOOD (2023)

Add to Collection

Article Immunology

Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation

Alan Kennedy, Erin Waters, Behzad Rowshanravan, Claudia Hinze, Cayman Williams, Daniel Janman, Thomas A. Fox, Claire Booth, Anne M. Pesenacker, Neil Halliday, Blagoje Soskic, Satdip Kaur, Omar S. Qureshi, Emma C. Morris, Shinji Ikemizu, Christopher Paluch, Jiandong Huo, Simon J. Davis, Emmanuel Boucrot, Lucy S. K. Walker, David M. Sansom

Summary: CD28 and CTLA-4 play important roles in regulating T cell immunity. The study found that CTLA-4 captures ligands through transendocytosis, and CD80 leads to ubiquitination and degradation of CTLA-4, while CD86 allows CTLA-4 to detach and recycle back to the cell surface. Clinically relevant mutations disrupt CD86 transendocytosis and are associated with autoimmune diseases.

NATURE IMMUNOLOGY (2022)

Add to Collection

Article Cell Biology

Therapeutic gene editing of T cells to correct CTLA-4 insufficiency

Thomas Andrew Fox, Benjamin Christopher Houghton, Lina Petersone, Erin Waters, Natalie Mona Edner, Alex McKenna, Olivier Preham, Claudia Hinze, Cayman Williams, Adriana Silva de Albuquerque, Alan Kennedy, Anne Maria Pesenacker, Pietro Genovese, Lucy Sarah Kate Walker, Siobhan Oisin Burns, David Michael Sansom, Claire Booth, Emma Catherine Morris

Summary: A gene editing strategy was designed to insert the CTLA-4 cDNA into primary human T cells, restoring CTLA-4 expression and demonstrating the feasibility of using T cell gene therapy for CTLA-4 insufficiency.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Add to Collection

Review Biotechnology & Applied Microbiology

Genome Editing in Engineered T Cells for Cancer Immunotherapy

Chiara Bonini, Aude G. Chapuis, Michael Hudecek, Sonia Guedan, Chiara Magnani, Waseem Qasim

Summary: Gene editing technologies can address challenges in adoptive cellular therapy, such as therapy resistance, immune reactions, and immunosuppressive signals. These innovative approaches improve the efficacy and safety of cellular therapy, benefiting more patients.

HUMAN GENE THERAPY (2023)

Add to Collection

Meeting Abstract Biotechnology & Applied Microbiology

Investigation of chimeric FcγRIIIa receptor (cFcR) engineered 'Universal' T cells in combination with anti-CD20 monoclonal antibody

A. Etuk, C. Georgiadis, R. Preece, W. Qasim

HUMAN GENE THERAPY (2022)

Add to Collection

Meeting Abstract Biotechnology & Applied Microbiology

CRISPR-coupled CAR engineering of universal donor T cells for paediatric B-ALL

C. Georgiadis, G. Ottaviano, S. A. Gkazi, F. Syed, H. Zhan, A. Etuk, R. Preece, W. Qasim

HUMAN GENE THERAPY (2022)

Add to Collection

Meeting Abstract Biotechnology & Applied Microbiology

Virus-free production of CD20-targeted CAR-T cells via CRISPR-Cas9-mediated transgene insertion

O. Gough, R. Preece, H. Aldahshan, C. Georgiadis, W. Qasim

HUMAN GENE THERAPY (2022)

Add to Collection

Meeting Abstract Biotechnology & Applied Microbiology

Base edited universal'' CAR T cells against childhood AML

R. Kadirkamanathan, C. Georgiadis, A. Etuk, T. Braybrook, R. Preece, H. Zhan, W. Qasim

HUMAN GENE THERAPY (2022)

Add to Collection

Meeting Abstract Biotechnology & Applied Microbiology

Comparison of cytidine deaminase base editors for multiplexed editing of T cells

H. Aldahshan, R. Preece, H. Brezovjakova, C. Georgiadis, W. Qasim

HUMAN GENE THERAPY (2022)

Add to Collection

Meeting Abstract Biotechnology & Applied Microbiology

Base editing of HLA for the generation of 'universal' human keratinocytes

H. Brezovjakova, V. Jayarajan, O. Gough, A. Etuk, A. Petrova, W. L. Di, W. Qasim

HUMAN GENE THERAPY (2022)

Add to Collection

Article Allergy

Phenotype, genotype, treatment, and survival outcomes in patients with X-linked inhibitor of apoptosis deficiency

Linlin Yang, Claire Booth, Carsten Speckmann, Markus G. Seidel, Austen J. J. Worth, Gerhard Kindle, Arjan C. Lankester, Bodo Grimbacher, Andrew R. Gennery, Mikko R. J. Seppanen, Emma C. Morris, Siobhan O. Burns

Summary: XIAP deficiency presents with a wide spectrum of clinical features, with no clear genotype-phenotype correlation. Conservative management and hematopoietic stem-cell transplantation (HSCT) have different overall survival probabilities, with potential factors like HLH and myeloablative conditioning regimens impacting outcomes.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.